William Grogan
Senior Vice President and Chief Financial Officer at IDEX
Thanks, Eric. I'll start with our consolidated financial results on slide eight. Q3 orders of $781 million were up 1% overall and down 1% organically. We experienced orders growth in FMT, but some contraction in HST and FSD primarily driven by timing of some larger orders. Core demand rates remain positive across the segments. Third quarter sales of $824 million were up 16% overall and up 15% organically. We experienced record sales with double-digit organic increases across all three of our segments and strong performance across all geographies. Third quarter gross margin expanded by 250 basis points and adjusted gross margin expanded by 10 basis points compared to the prior year at 45.1%, driven by strong volume leverage and favorable price/cost, partially offset by higher employee-related costs.
Third quarter operating margin was 24.5%, up 190 basis points compared to the prior year. Adjusted operating margin was 24.9%, up 60 basis points. Incremental amortization related to the Nexsight and KZValve acquisitions unfavorably impacted adjusted operating margin by 30 basis points. I'll discuss additional drivers of adjusted operating income on the next slide. Our Q3 effective tax rate was 21.8%. It decreased compared to the prior year ETR of 23.4%, primarily driven due to the tax benefits associated with the sale of the Knight business. Third quarter net income was $179 million, which resulted in an EPS of $2.36.
Adjusted net income was $162 million, resulting in an EPS and adjusted EPS of $2.14, up $0.35 or 20% over prior year. Finally, free cash flow for the quarter was $182 million, 112% of adjusted net income. This was a record free cash flow for us, mainly driven by higher earnings. We are seeing inventory levels stabilize and expect further reductions as we exit the year. Moving on to slide nine, which details the drivers of our adjusted operating income. Third quarter adjusted operating income increased $28 million compared to last year. Our 15% organic growth contributed approximately $26 million flowing through at our prior year adjusted gross margin rate.
We levered well on the volume increase, and we had strong price capture to offset inflation headwinds. Price/cost was accretive to margins and has returned to historic levels, driven by our FMT and HST segments with FSD making improvement sequentially versus the second quarter. We experienced slight positive mix of $2 million in various parts of the portfolio. We reinvested $6 million, taking the form of engineering and commercial resources in the businesses and M&A and DE&I resources at corporate. Tracking to the $0.20 to $0.25 of full year spend we highlighted at the beginning of the year. Lastly, discretionary spending increased by $6 billion versus last year, which is slightly below the second quarter of 2022, and -- as we said last quarter, we have reached a more normalized post-COVID spend rate on significantly higher sales volume.
This delivered a strong organic flow-through of 31% in the quarter. Flow-through is then negatively impacted by the dilutive impact of acquisitions, divestitures and FX getting us to a reported flow-through of 30%. With that, I'll provide a deeper look at our segment performance. I'm on page 10. In our Fluid & Metering Technology segment, we experienced excellent order and sales performance with organic growth of 2% and 17%, respectively. FMT adjusted operating margin expanded by 250 basis points versus last year. The increase included 80 basis points of headwind due to the incremental amortization related to the Nexsight and KZValve acquisitions.
We experienced continued strong volume leverage and operational productivity as well as favorable price/cost. Our industrial markets continue to exhibit steady demand with tailwinds from energy, mining and infrastructure tempered a bit by some European softness. Our outlook for our municipal water businesses continues to be positive. We see healthy quoting activities in sync with underlying market trends of growing urbanization, further CCTV inspection adoption and infrastructure investments in the U.S. Agriculture remains strong. We are seeing positive signals from both our OEMs and distributors. Commodity prices remain high and increased fuel and fertilizer costs are incenting farmers to invest in precision technologies.
Our investment in Banjo's process automation have improved our delivery, putting us in a good position to capture share and we continue to leverage KZValve's expertise and technology to enhance our product offerings. Our energy business is performing well with strong oil and LPG price support. We continue to see favorable results upstream with midstream investments lagging a bit due to supply chain constraints at our customers and larger project spend delays. Moving on to the Health and Technology segment. Orders contracted by 4%, but sales were strong at 13%. Our backlog position remains robust. The contraction in orders were driven by several large orders that delayed out of the quarter.
European capital goods softness and tough comparables from the prior year where we grew orders organically by 44%. HST adjusted operating margin contracted by 70 basis points versus last year. The segment experienced strong volume leverage and positive price/cost, which was more than offset by increased engineering and resource investments, higher discretionary spending and some inefficiencies incurred as we continue to onboard labor to meet demand and navigate supply chain challenges. We continue to experience strong demand for analytical instrumentation in chromatography and mass spectrometry as well as next-gen sequencing technology for oncology testing and research.
Our targeted growth initiatives tied to global broadband and energy efficient fuel cells are performing very well. Two great examples of how we are leveraging our tech in fast-growing niche markets. The semiconductor market remains steady. We see customer-related supply chain issues driving some slowing, but we are offsetting this headwind through share gains. We provide consumables and technology to drive fab efficiency, buffering us for some of the capex slowdown on the new equipment side. Our material processing business remains strong on continued pharma and biopharma demand. We are seeing some order slowdown due to investment delays by our customers, but our funnel remains strong and of high quality.
Our HST industrial market performance is very much like the experience in FMT. Finally, turning to our Fire Safety and Diversified Products segment. Orders were flat year-over-year as a difficult quarter-over-quarter comparables in our dispensing business was offset by strong growth by the balance of the portfolio. Sales were quite strong with an organic increase of 14%. FSD adjusted operating margin expanded by 70 basis points versus the third quarter of 2021, driven by strong volume leverage, partly offset by pressure on price cost and higher employee-related costs. Although price cost is still dilutive to margins, it did improve sequentially.
Our dispensing business performed well with the delivery of North American project volume and continued strength in the global architectural paint market. But orders were down 30% year-over-year due to large North American replenishment orders that we received last year. Within our fire business, OEMs continue to struggle with supply chain constraints. But we did see positive organic growth from price realization, improved execution and favorable performance in loose equipment. On the rescue side, we continue to win with our latest generation E3 tool, bringing enhanced tool features to the market. Finally, [Indecipherable] experienced strong results across industrial, automotive and energy markets.We continue to win share by having shorter lead times and material availability. On the auto side, we are outperforming the market by capturing share on new platforms and winning content on priority high-volume vehicles.
With that, I'd like to provide an update on our outlook for the fourth quarter and full year 2022. I'm on slide 11, which lays out our updated guidance. For the fourth quarter of 2022, we are projecting organic revenue growth of approximately 9% and operating margin of approximately 23.5%. We expect that the volume will decrease sequentially from the third to fourth quarter due to normal seasonality and scheduled maintenance shutdowns. Q4 forecasted op margin is down versus Q3 due to lost leverage on lower revenues. We expect GAAP EPS to range from $1.75 to $1.80 and adjusted EPS to range from $1.92 to $1.97.
Turning to the full year. Given our strong performance in the prior three quarters, we are raising our full year guidance. We now expect full year organic revenue growth of approximately 12%. We expect GAAP EPS to range between $7.75 to $7.80 and expect EPS to range from $8.04 to $8.09. Our operating margin for the full year is expected to be approximately 24%, and we expect free cash flow as a percent of adjusted net income to range from 75% to 80%.
With that, I would like to turn it back to Eric for closing remarks.